Lannett To Close And Sell NY Liquids Plant As Part Of Restructuring Plans

Cost Savings Of $20m Annually Targeted; Portfolio Also Rationalized

Lannett is once again taking the axe to its operations in order to tighten its focus and save on costs, including the planned divestment of its liquids generics manufacturing facility in Carmel, New York.

structuring
Lannett cited challenging business conditions as it wielded the axe • Source: Alamy

Amid longstanding and now accelerated weakness in its base business, Lannett has announced a further restructuring and cost-saving initiative that all but ends its ambitions in the liquid generics space.

Future investment will prioritize more “durable and attractive assets,” while Lannett envisions cost savings of $20m per year under its...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Business

More from Generics Bulletin